{"organizations": [], "uuid": "5b4a944e5a67f0f7dd5f44274a8ab889dc5cfdd9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180227.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-activation-of-16th-clinical-trial-site-idUSASB0C7ON", "country": "US", "domain_rank": 408, "title": "BRIEF-Actinium Pharmaceuticals Announces Activation Of 16th Clinical Trial Site", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.995, "site_type": "news", "published": "2018-02-27T20:49:00.000+02:00", "replies_count": 0, "uuid": "5b4a944e5a67f0f7dd5f44274a8ab889dc5cfdd9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-activation-of-16th-clinical-trial-site-idUSASB0C7ON", "ord_in_thread": 0, "title": "BRIEF-Actinium Pharmaceuticals Announces Activation Of 16th Clinical Trial Site", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - actinium pharmaceuticals inc", "sentiment": "neutral"}, {"name": "sierra", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Actinium Pharmaceuticals Inc:\n* ACTINIUM PHARMACEUTICALS ANNOUNCES ACTIVATION OF SIXTEENTH CLINICAL TRIAL SITE IN THE PIVOTAL PHASE 3 SIERRA TRIAL FOR IOMAB-B\n* ACTINIUM PHARMACEUTICALS INC - ACTIVATED SIXTEEN CLINICAL TRIAL SITES IN PHASE 3 SIERRA TRIAL​\n* ACTINIUM PHARMACEUTICALS INC - ‍EXPECTS TO PROVIDE UPDATES ON IOMAB-B SIERRA TRIAL IN LINE WITH PREVIOUSLY STATED OBJECTIVES FOR 2018 AND 2019​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T20:49:00.000+02:00", "crawled": "2018-02-28T13:00:40.000+02:00", "highlightTitle": ""}